GLP-1 medications are known for weight loss. Increasingly, they are known for cardiovascular protection (the SELECT trial). But the FLOW trial data, published in the New England Journal of Medicine in 2024, revealed something that may ultimately prove even more significant: these medications protect the kidneys.
Chronic kidney disease (CKD) affects approximately 37 million Americans, including roughly 1 in 3 adults with diabetes. It is a progressive condition that, at its worst, leads to dialysis or transplant. And it has been undertreated for decades. The FLOW trial changes the treatment calculus.
The Trial
FLOW (Evaluate Renal Function with Semaglutide Once Weekly) enrolled 3,533 adults with type 2 diabetes and chronic kidney disease across multiple countries. Participants were randomized to receive semaglutide (1.0 mg weekly) or placebo, on top of their standard care (which already included renin-angiotensin system inhibitors — the current standard for kidney protection in diabetes).
The primary outcome was a composite of major kidney disease events: the onset of kidney failure (dialysis, transplant, or eGFR below 15), at least a 50% reduction in kidney function from baseline, or death from kidney-related or cardiovascular causes.
The trial was designed to run for several years. It was stopped early — at a median follow-up of 3.4 years — because a prespecified interim analysis showed clear positive efficacy. The independent data monitoring committee determined that continuing to give some patients placebo was no longer ethical.
The Results
| Outcome | Risk Reduction with Semaglutide |
|---|---|
| Major kidney disease events (primary) | 24% reduction (HR 0.76, p=0.0003) |
| Major cardiovascular events (MACE) | 18% reduction |
| All-cause death | 20% reduction |
| eGFR decline (rate of kidney function loss) | Slowed by 1.16 ml/min/1.73m²/year |
These are not marginal improvements. A 24% reduction in major kidney events, an 18% reduction in cardiovascular events, and a 20% reduction in all-cause mortality — on top of existing standard-of-care therapy — represents a meaningful clinical advance for a patient population with very high residual risk.
Why This Is Underreported
The FLOW trial generated far less media attention than the weight loss trials. This is partly because kidney disease is not as culturally visible as obesity, and partly because the trial population — older adults with type 2 diabetes and existing kidney disease — does not generate the same consumer interest as weight loss medications.
But in terms of clinical significance, FLOW may be the most important GLP-1 trial published to date. Kidney failure is devastating. Dialysis costs approximately $90,000 per patient per year and dramatically reduces quality of life. A 24% reduction in the progression toward kidney failure, achieved with a once-weekly injection, has the potential to prevent tens of thousands of dialysis starts per year in the U.S. alone.
How This Relates to Weight Loss Patients
The FLOW trial studied semaglutide at 1.0 mg weekly (the Ozempic dose), not the 2.4 mg dose used for weight loss (Wegovy). And the participants had type 2 diabetes and established kidney disease — a different population than most weight loss patients.
However, the kidney-protective mechanism is likely related to the metabolic improvements that semaglutide produces across populations: reduced inflammation (measured by CRP), improved blood sugar control, lower blood pressure, reduced body weight, and improved lipid profiles. These effects are not limited to the diabetic kidney disease population — they occur in obesity patients too.
For patients taking GLP-1 medications for weight loss who also have risk factors for kidney disease — diabetes, hypertension, family history of CKD — the FLOW data adds another reason to continue therapy beyond the scale number. The kidney-protective benefits may be occurring whether or not kidney disease has been formally diagnosed.
If you have diabetes and kidney concerns: Ask your doctor whether semaglutide has been considered as part of your kidney protection strategy. The FLOW data supports its use on top of existing standard-of-care medications (like ACE inhibitors or ARBs and SGLT2 inhibitors). It is not a replacement for these medications — it is an addition that provides further risk reduction.
The Expanding Benefits Beyond Weight Loss
FLOW joins a growing list of clinical outcomes that GLP-1 medications have demonstrated beyond weight management: cardiovascular event reduction (SELECT), kidney disease progression (FLOW), heart failure symptom improvement (STEP-HFpEF), and emerging data on neurological protection and addiction modulation.
These benefits are reshaping how physicians and payers think about GLP-1 medications. They are not "weight loss drugs" with some interesting side benefits. They are metabolic therapies with weight loss, cardiovascular, kidney, and potentially neurological effects — medications whose benefits accumulate across multiple organ systems simultaneously.
For patients, this broader framing matters because it strengthens the case for insurance coverage, Medicare access, and long-term therapy. A medication that prevents kidney failure and heart attacks is harder for insurers to deny than a medication that helps people lose weight.
Explore GLP-1 Providers
Compare providers offering semaglutide and tirzepatide — whether your primary goal is weight loss, metabolic health, or both.
Compare Providers